Merck’s experimental Covid-19 treatment pill, called molnupiravir |
The Food and Drug Administration granted emergency
authorization Wednesday to Pfizer’s Covid treatment pill, a major
milestone that promises to revolutionize the fight against the virus.
The
medication, which is recommended for people at a high risk of developing severe Covid-19,
could be available to patients as early as this weekend. Pfizer CEO Albert
Bourla told the press earlier this month the company has already shipped some
of the pills to the U.S. so they can be prescribed as soon as the FDA
authorization comes through. The Centers for Disease Control and Prevention is
expected to quickly follow suit with its seal of approval, authorizing its distribution.
The
FDA cleared the pill for patients 12 and up with mild to moderate Covid who are
most likely to end up hospitalized or not survive. The agency said it should be
prescribed as soon as possible after diagnosis and within five days of symptom
onset.
“Today’s authorization introduces the first treatment for
COVID-19 that is in the form of a pill that is taken orally — a major step
forward in the fight against this global pandemic,” Dr. Patrizia Cavazzoni,
director of the FDA’s Center for Drug Evaluation and Research, said in a
statement. “This authorization provides a new tool to combat COVID-19 at a
crucial time in the pandemic as new variants emerge and promises to make
antiviral treatment more accessible to patients who are at high risk for progression
to severe COVID-19.”